亚太药业: 半年报监事会决议公告

Group 1 - The company held its fourth meeting of the eighth supervisory board on August 28, 2025, with all three supervisors participating in the voting [1] - The supervisory board approved the proposal for credit impairment losses and asset impairment losses with a unanimous vote, stating that it aligns with accounting standards and reflects the company's actual situation [1] - The supervisory board also approved the 2025 semi-annual report and its summary, confirming that the report's preparation and review processes comply with legal and regulatory requirements [2]